Back in 2013 , Questcor ( a company Mallinckrodt later acquired ) bought a competitor to Acthar called Synacthen .The FTC alleged that Mallinckrodt kept other companies from selling the competing Acthar lower price .the FTC of the settlement the FTC charged the company with violating antitrust laws Mallinckrodt had to agree to license Synacthen to Marathon Pharmaceuticals to treat infantile spasms and nephrotic Mallinckrodt in the US.’ ’